Details of Host Protein-DME Interaction (HOSPPI)
| General Information of Drug-Metabolizing Enzyme (DME ID: DME0227) | |||||
|---|---|---|---|---|---|
| DME Name | Retinoic acid 4-hydroxylase 26A1 (CYP26A1), Homo sapiens | DME Info | |||
| UniProt ID | |||||
| EC Number | EC: 1.14.13.- (Click to Show/Hide the Complete EC Tree) | ||||
| Lineage | Species: Homo sapiens (Click to Show/Hide the Complete Species Lineage) | ||||
| Interactome | |||||
| Disease Specific Interactions between Host Protein and DME (HOSPPI) | |||||
|---|---|---|---|---|---|
| ICD Disease Classification Healthy | |||||
| ICD-11: Healthy | Click to Show/Hide the Full List of HOSPPI: 3 HOSPPI | ||||
| Histone modification | |||||
| Histone deacetylase 1 (HDAC1) | Health | Repression | |||
| Uniprot ID | |||||
| Interaction Name | HDAC1-CYP26A1 interaction | [1] | |||
| Studied Cell Lines | Embryonic stem cell | ||||
| Description | Histone deacetylase 1 (HDAC1) is reported to deacetylate the CYP26A1 gene and thereby represses the transcriptional activity of the drug-metabolizing enzyme Retinoic acid 4-hydroxylase 26A1. As a result, the interaction between HDAC1 and CYP26A1 can inhibit the drug-metabolizing process of Retinoic acid 4-hydroxylase 26A1. | ||||
| Histone deacetylase 2 (HDAC2) | Health | Repression | |||
| Uniprot ID | |||||
| Interaction Name | HDAC2-CYP26A1 interaction | [1] | |||
| Studied Cell Lines | Embryonic stem cell | ||||
| Description | Histone deacetylase 2 (HDAC2) is reported to deacetylate the CYP26A1 gene and thereby represses the transcriptional activity of the drug-metabolizing enzyme Retinoic acid 4-hydroxylase 26A1. As a result, the interaction between HDAC2 and CYP26A1 can inhibit the drug-metabolizing process of Retinoic acid 4-hydroxylase 26A1. | ||||
| Histone deacetylase 3 (HDAC3) | Health | Repression | |||
| Uniprot ID | |||||
| Interaction Name | HDAC3-CYP26A1 interaction | [1] | |||
| Studied Cell Lines | Embryonic stem cell | ||||
| Description | Histone deacetylase 3 (HDAC3) is reported to deacetylate the CYP26A1 gene and thereby represses the transcriptional activity of the drug-metabolizing enzyme Retinoic acid 4-hydroxylase 26A1. As a result, the interaction between HDAC3 and CYP26A1 can inhibit the drug-metabolizing process of Retinoic acid 4-hydroxylase 26A1. | ||||
| ICD Disease Classification 02 Neoplasms | |||||
| ICD-11: 2A00 Brain cancer | Click to Show/Hide the Full List of HOSPPI: 9 HOSPPI | ||||
| DNA methylation | |||||
| DNA methyltransferase (DNMT) | Medulloblastoma | Significant hypermethylation | |||
| Interaction Name | DNMT-CYP26A1 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Significant hypermethylation p-value: 7.22E-52; delta-beta: 3.77E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hyper-methylate the CYP26A1 gene, which leads to a significantly decreased expression of the drug-metabolizing enzyme Retinoic acid 4-hydroxylase 26A1. As a result, the interaction between DNMT and CYP26A1 can significantly affect the drug-metabolizing process of Retinoic acid 4-hydroxylase 26A1. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| DNA methyltransferase (DNMT) | Brain neuroepithelial tumour | Significant hypermethylation | |||
| Interaction Name | DNMT-CYP26A1 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Significant hypermethylation p-value: 3.84E-08; delta-beta: 3.06E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hyper-methylate the CYP26A1 gene, which leads to a significantly decreased expression of the drug-metabolizing enzyme Retinoic acid 4-hydroxylase 26A1. As a result, the interaction between DNMT and CYP26A1 can significantly affect the drug-metabolizing process of Retinoic acid 4-hydroxylase 26A1. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| DNA methyltransferase (DNMT) | Central neurocytoma | Significant hypomethylation | |||
| Interaction Name | DNMT-CYP26A1 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Significant hypomethylation p-value: 1.13E-05; delta-beta: -4.31E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hypo-methylate the CYP26A1 gene, which leads to a significantly increased expression of the drug-metabolizing enzyme Retinoic acid 4-hydroxylase 26A1. As a result, the interaction between DNMT and CYP26A1 can significantly affect the drug-metabolizing process of Retinoic acid 4-hydroxylase 26A1. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| DNA methyltransferase (DNMT) | Oligodendroglial tumour | Significant hypermethylation | |||
| Interaction Name | DNMT-CYP26A1 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Significant hypermethylation p-value: 1.56E-05; delta-beta: 4.61E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hyper-methylate the CYP26A1 gene, which leads to a significantly decreased expression of the drug-metabolizing enzyme Retinoic acid 4-hydroxylase 26A1. As a result, the interaction between DNMT and CYP26A1 can significantly affect the drug-metabolizing process of Retinoic acid 4-hydroxylase 26A1. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| DNA methyltransferase (DNMT) | Multilayered rosettes embryonal tumour | Moderate hypermethylation | |||
| Interaction Name | DNMT-CYP26A1 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Moderate hypermethylation p-value: 9.70E-05; delta-beta: 2.66E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to moderatly hyper-methylate the CYP26A1 gene, which leads to a moderatly decreased expression of the drug-metabolizing enzyme Retinoic acid 4-hydroxylase 26A1. As a result, the interaction between DNMT and CYP26A1 can moderatly affect the drug-metabolizing process of Retinoic acid 4-hydroxylase 26A1. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| DNA methyltransferase (DNMT) | Myxopapillary ependymoma | Significant hypomethylation | |||
| Interaction Name | DNMT-CYP26A1 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Significant hypomethylation p-value: 7.17E-11; delta-beta: -3.72E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hypo-methylate the CYP26A1 gene, which leads to a significantly increased expression of the drug-metabolizing enzyme Retinoic acid 4-hydroxylase 26A1. As a result, the interaction between DNMT and CYP26A1 can significantly affect the drug-metabolizing process of Retinoic acid 4-hydroxylase 26A1. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| DNA methyltransferase (DNMT) | RELA YAP fusion ependymoma | Moderate hypermethylation | |||
| Interaction Name | DNMT-CYP26A1 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Moderate hypermethylation p-value: 7.86E-13; delta-beta: 2.66E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to moderatly hyper-methylate the CYP26A1 gene, which leads to a moderatly decreased expression of the drug-metabolizing enzyme Retinoic acid 4-hydroxylase 26A1. As a result, the interaction between DNMT and CYP26A1 can moderatly affect the drug-metabolizing process of Retinoic acid 4-hydroxylase 26A1. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| DNA methyltransferase (DNMT) | Third ventricle chordoid glioma | Significant hypomethylation | |||
| Interaction Name | DNMT-CYP26A1 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Significant hypomethylation p-value: 3.45E-07; delta-beta: -4.42E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hypo-methylate the CYP26A1 gene, which leads to a significantly increased expression of the drug-metabolizing enzyme Retinoic acid 4-hydroxylase 26A1. As a result, the interaction between DNMT and CYP26A1 can significantly affect the drug-metabolizing process of Retinoic acid 4-hydroxylase 26A1. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| DNA methyltransferase (DNMT) | Atypical teratoid/rhabdoid tumour | Moderate hypermethylation | |||
| Interaction Name | DNMT-CYP26A1 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Moderate hypermethylation p-value: 1.35E-05; delta-beta: 2.18E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to moderatly hyper-methylate the CYP26A1 gene, which leads to a moderatly decreased expression of the drug-metabolizing enzyme Retinoic acid 4-hydroxylase 26A1. As a result, the interaction between DNMT and CYP26A1 can moderatly affect the drug-metabolizing process of Retinoic acid 4-hydroxylase 26A1. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| ICD-11: 2A01 Meningeal tumour | Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI | ||||
| DNA methylation | |||||
| DNA methyltransferase (DNMT) | Meningioma | Moderate hypermethylation | |||
| Interaction Name | DNMT-CYP26A1 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Moderate hypermethylation p-value: 7.21E-32; delta-beta: 2.62E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to moderatly hyper-methylate the CYP26A1 gene, which leads to a moderatly decreased expression of the drug-metabolizing enzyme Retinoic acid 4-hydroxylase 26A1. As a result, the interaction between DNMT and CYP26A1 can moderatly affect the drug-metabolizing process of Retinoic acid 4-hydroxylase 26A1. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| ICD-11: 2B30 Lymphoma | Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI | ||||
| DNA methylation | |||||
| DNA methyltransferase (DNMT) | Lymphoma | Significant hypomethylation | |||
| Interaction Name | DNMT-CYP26A1 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Significant hypomethylation p-value: 9.12E-34; delta-beta: -5.79E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hypo-methylate the CYP26A1 gene, which leads to a significantly increased expression of the drug-metabolizing enzyme Retinoic acid 4-hydroxylase 26A1. As a result, the interaction between DNMT and CYP26A1 can significantly affect the drug-metabolizing process of Retinoic acid 4-hydroxylase 26A1. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| ICD-11: 2C12 Liver cancer | Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI | ||||
| DNA methylation | |||||
| DNA methyltransferase (DNMT) | Liver cancer | Significant hypermethylation | |||
| Interaction Name | DNMT-CYP26A1 interaction | ||||
| The Methylation Level of Disease Section Compare with the Other Disease Section | Significant hypermethylation p-value: 4.46E-02; delta-beta: 6.39E-02 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hyper-methylate the CYP26A1 gene, which leads to a significantly decreased expression of the drug-metabolizing enzyme Retinoic acid 4-hydroxylase 26A1. As a result, the interaction between DNMT and CYP26A1 can significantly affect the drug-metabolizing process of Retinoic acid 4-hydroxylase 26A1. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue adjacent to the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
DME methylation in tissue other than the diseased tissue of patients
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| ICD-11: 2D50 Brain cancer metastasis | Click to Show/Hide the Full List of HOSPPI: 2 HOSPPI | ||||
| DNA methylation | |||||
| DNA methyltransferase (DNMT) | Esthesioneuroblastoma | Moderate hypermethylation | |||
| Interaction Name | DNMT-CYP26A1 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Moderate hypermethylation p-value: 1.93E-02; delta-beta: 2.29E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to moderatly hyper-methylate the CYP26A1 gene, which leads to a moderatly decreased expression of the drug-metabolizing enzyme Retinoic acid 4-hydroxylase 26A1. As a result, the interaction between DNMT and CYP26A1 can moderatly affect the drug-metabolizing process of Retinoic acid 4-hydroxylase 26A1. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| DNA methyltransferase (DNMT) | Posterior fossa ependymoma | Moderate hypermethylation | |||
| Interaction Name | DNMT-CYP26A1 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Moderate hypermethylation p-value: 3.07E-23; delta-beta: 2.18E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to moderatly hyper-methylate the CYP26A1 gene, which leads to a moderatly decreased expression of the drug-metabolizing enzyme Retinoic acid 4-hydroxylase 26A1. As a result, the interaction between DNMT and CYP26A1 can moderatly affect the drug-metabolizing process of Retinoic acid 4-hydroxylase 26A1. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| ICD Disease Classification 05 Endocrine/nutritional/metabolic diseases | |||||
| ICD-11: 5A61 Pituitary gland hypofunction | Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI | ||||
| DNA methylation | |||||
| DNA methyltransferase (DNMT) | Chordoma | Moderate hypermethylation | |||
| Interaction Name | DNMT-CYP26A1 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Moderate hypermethylation p-value: 2.08E-03; delta-beta: 2.41E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to moderatly hyper-methylate the CYP26A1 gene, which leads to a moderatly decreased expression of the drug-metabolizing enzyme Retinoic acid 4-hydroxylase 26A1. As a result, the interaction between DNMT and CYP26A1 can moderatly affect the drug-metabolizing process of Retinoic acid 4-hydroxylase 26A1. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| References | |||||
|---|---|---|---|---|---|
| 1 | Retinoic acid and histone deacetylases regulate epigenetic changes in embryonic stem cells. J Biol Chem. 2014 Jul 11;289(28):19519-30. | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.